IN SUPPORTING THE DISTRIBUTION & ADMINISTRATION OF COVID-19 VACCINES, OWS HAS FOUR KEY GOALS, TENETS, AND ARCHITECTURE

**IN SUPPORT OF THE DISTRIBUTION & ADMINISTRATION OF COVID-19 VACCINES, OWS HAS FOUR KEY GOALS, TENETS, AND ARCHITECTURE**

**CONTROL/VISIBILITY**
Where vaccines and secondary item kits are at all times in the process of distribution and ensuring the vaccines go to prioritized groups as determined by policy.

**UPTAKE**
How many vaccines were administered per location per day to match supply with demand.

**COVERAGE**
Deliver vaccines beyond the normal brick and mortar facilities, including potential mobile or on-site delivery of vaccine to long-term healthcare facilities and other hard to reach populations.

**TRACEABILITY**
Confirm which of the approved vaccines were administered:
- Regardless of location (private/public)
- Reminder to return for second dose
- Administer the correct second dose

**DISTRIBUTION AND ADMINISTRATION OF A COVID-19 VACCINE FOUR KEY TENETS**

- **Reduce morbidity and mortality of COVID-19 disease through effective and efficient distribution of COVID-19 vaccines**
- **Support rapid vaccine distribution based on CDC guidance for states’ immunizations services**
- **Ensure safety and effectiveness of COVID-19 vaccines**
- **Assist with the return to pre-pandemic quality of life**

**TRIALS**
FDA
Based on data from clinical trials, vaccine candidate is submitted for Emergency Use Authorization (EUA) or Biologics License Application (BLA)
- Reviews EUA/BLA application
- Approves EUA/BLA application
- Oversees ongoing reporting
- Pharmacovigilance

**MANUFACTURING**
Manufacturer
Vaccine is being manufactured concurrent with clinical trials, and upon EUA/BLA and CDC recommendation, vaccine is ready to ship

**ADMINISTRATION SITES**
Vaccines, upon EUA/BLA, are ready to ship to:
- Pharmacies
- Nursing homes
- Public Clinics
- Hospitals
- Doctor’s offices and Mobile Clinics
- Military Treatment Facilities

**DISTRIBUTION FACILITIES**
Vaccines & associated ancillary kits (gargles, needles, and alcohol swabs) will be shipped concurrently to distribution depots and facilities

**DISTRIBUTOR**
Maximize use of existing pharmaceutical distribution infrastructure
- Central Distributor established for kitting & distribution operations
- IT infrastructure supports ordering, distribution, administration, and tracking end-to-end

**PHARMACOVIGILANCE (FDA & CDC)**
24 month post trial monitoring for adverse effects/additional safety feature

**OWS & CDC**
Allocation of initial/limited doses will be based on CDC prioritization models
- Independent advisory panel (Advisory Committee on Immunization Practices with input from Nat’l Academies of Science) informs CDC prioritization
- Initial/limited doses will be allocated for specific groups
  - Oversees distribution of vaccine
  - Tracks product that is delivered/administered

**MANUFACTURER**
Vaccine is being manufactured concurrent with clinical trials, and upon EUA/BLA and CDC recommendation, vaccine is ready to ship

**DISTRIBUTION FACILITIES**
Vaccines & associated ancillary kits (gargles, needles, and alcohol swabs) will be shipped concurrently to distribution depots and facilities

**DISTRIBUTOR**
Maximize use of existing pharmaceutical distribution infrastructure
- Central Distributor established for kitting & distribution operations
- IT infrastructure supports ordering, distribution, administration, and tracking end-to-end

**PHARMACOVIGILANCE (FDA & CDC)**
24 month post trial monitoring for adverse effects/additional safety feature